Exec Chat: As Reimbursement Questions Get Answers, iRhythm Looks To The Future
Medtech Insight caught up again with iRhythm CEO Quentin Blackford about his vision for the company as it plans for the next five to ten years of expansion in the remote cardiac monitoring and arrhythmia diagnostics market.
You may also be interested in...
The ZEUS (Zio ECG Utilization Software) system for iRhythm’s Zio Watch detects and characterizes atrial fibrillation over time to aid doctors in diagnosing the condition. The company expects to begin commercializing it next year.
Analysts expect iRhythm to shift more of its long-term remote cardiac monitoring operations to its California facility to take advantage of new Medicare reimbursement rates set by the US Centers for Medicare and Medicaid Services.
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights AI trends in medtech, Exec Chats with iRhythm and medical robotics authority Moshe Shoham, and key FDA updates.